2373. Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial Anaerobic Isolates

BACKGROUND: Delafloxacin (DLX) is a broad-spectrum fluoroquinolone (FQ) antibacterial; approved in 2017 by the Food and Drug Administration for treatment of acute bacterial skin and skin structure infections (ABSSSIs). DLX is in clinical development for community-acquired bacterial pneumonia (CABP)....

Descripción completa

Detalles Bibliográficos
Autores principales: Shortridge, Dee, McCurdy, Sandra P, Rhomberg, Paul R, Huband, Michael D, Flamm, Robert K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255597/
http://dx.doi.org/10.1093/ofid/ofy210.2026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255597/
http://dx.doi.org/10.1093/ofid/ofy210.2026

Ejemplares similares